Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. (28th May 2020)
- Record Type:
- Journal Article
- Title:
- Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. (28th May 2020)
- Main Title:
- Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma
- Authors:
- Choi, Bongkum
Lee, Joo Sang
Kim, Sung Joo
Hong, Doopyo
Park, Jae Berm
Lee, Ki-Young - Abstract:
- Abstract: The efficacy of an immune checkpoint blockade has been demonstrated against various types of cancer, but its suitability has not been fully proven for therapies specifically targeting sarcoma. We conducted a pan-cancer tumor data analysis to identify key immune-related variables strongly associated with sarcoma prognosis, and we explored whether these expected factors are functionally correlated with anti-PD-1 therapy in humanized (Hu) NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice xenografted with dedifferentiated liposarcoma (DDLPS). We found that an abundance of hCD8 + T cells and hNK cells was functionally associated with anti-PD-1 effects in the Hu-NSG DDLPS mice. Phenotypically, these cells were shown to be hCD8 + IFNγ +, hCD8 + PD-1 +, hCD8 + Ki-67 +, hCD56 + IFNγ +, hCD56 + PD-1 +, and hCD56 + Ki-67 + cells and were enriched in splenocytes and tumor-infiltrating lymphocytes (TILs) of Hu-NSG DDLPS mice treated with anti-PD-1 antibody. Moreover, a considerable increase in activated hCD56 + NKp46 + NKG2D + NK cells was also detected. Our findings suggest that hCD8 + T and hNK subsets play a pivotal role in anti-DDLPS tumor effects of anti-PD-1 therapy. The results provide clinical reference for advanced anti-PD-1 therapy targeting sarcoma tumors including DDLPS. Highlights: The efficacy of immune checkpoint blockade has been never proven in sarcoma. Immune-related variables are associated with the prognosis of sarcoma cancers. hCD8 + T and hNK cells areAbstract: The efficacy of an immune checkpoint blockade has been demonstrated against various types of cancer, but its suitability has not been fully proven for therapies specifically targeting sarcoma. We conducted a pan-cancer tumor data analysis to identify key immune-related variables strongly associated with sarcoma prognosis, and we explored whether these expected factors are functionally correlated with anti-PD-1 therapy in humanized (Hu) NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice xenografted with dedifferentiated liposarcoma (DDLPS). We found that an abundance of hCD8 + T cells and hNK cells was functionally associated with anti-PD-1 effects in the Hu-NSG DDLPS mice. Phenotypically, these cells were shown to be hCD8 + IFNγ +, hCD8 + PD-1 +, hCD8 + Ki-67 +, hCD56 + IFNγ +, hCD56 + PD-1 +, and hCD56 + Ki-67 + cells and were enriched in splenocytes and tumor-infiltrating lymphocytes (TILs) of Hu-NSG DDLPS mice treated with anti-PD-1 antibody. Moreover, a considerable increase in activated hCD56 + NKp46 + NKG2D + NK cells was also detected. Our findings suggest that hCD8 + T and hNK subsets play a pivotal role in anti-DDLPS tumor effects of anti-PD-1 therapy. The results provide clinical reference for advanced anti-PD-1 therapy targeting sarcoma tumors including DDLPS. Highlights: The efficacy of immune checkpoint blockade has been never proven in sarcoma. Immune-related variables are associated with the prognosis of sarcoma cancers. hCD8 + T and hNK cells are associated with the anti-PD-1 effects in DDLPS. hCD8 + T and hNK subsets might play a role for anti-DDLPS tumor effects. … (more)
- Is Part Of:
- Cancer letters. Volume 478(2020)
- Journal:
- Cancer letters
- Issue:
- Volume 478(2020)
- Issue Display:
- Volume 478, Issue 2020 (2020)
- Year:
- 2020
- Volume:
- 478
- Issue:
- 2020
- Issue Sort Value:
- 2020-0478-2020-0000
- Page Start:
- 56
- Page End:
- 69
- Publication Date:
- 2020-05-28
- Subjects:
- Humanized mouse model -- Patient-derived xenograft -- Anti-PD-1 antibody -- Dedifferentiated liposarcoma -- Immunotherapy
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2020.02.042 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 13414.xml